Please login to the form below

Not currently logged in
Email:
Password:

Columbia Laboratories retires all debt

Columbia Laboratories has sold its progesterone-related assets and 11.2m shares of common stock to Watson Pharmaceuticals to become debt-free
Columbia Laboratories has closed the sale of its progesterone-related assets and 11.2m shares of common stock to Watson Pharmaceuticals and is debt-free, the company has announced. Columbia now has over $25m in cash and approximately 84 million common shares outstanding.

The company received $47m in cash from Watson; Watson also forgave the interest on a $15m loan it had given Columbia on June 1, 2010. Columbia used approximately $16m of the initial proceeds to pre-pay the balance of the minimum royalty payments due in November 2010 to PharmaBio Development, and $26m, together with stock and warrants, to pre-pay the entire balance of the $40m in convertible notes due by December 31, 2011.

Becoming debt-free has improved the company's outlook significantly, according to Frank C Condella, Jr, president and chief executive officer of Columbia. 

"In the near term, Columbia will focus on the smooth transfer of domestic commercial operations for Crinone 8 per cent (progesterone gel) to Watson, completing the PREGNANT study of Prochieve 8 per cent (progesterone gel), and developing with Watson the next generation progesterone product," he said in a statement. 

The PREGNANT study is a randomised, double-blind, placebo controlled phase III trial to evaluate the safety and efficacy of Prochieve to reduce the risk of preterm birth in women with a cervical length between 1.0cm and 2.0cm as measured by transvaginal ultrasound at mid-pregnancy. 

Columbia's business now consists of its royalty and manufacturing revenues, potential milestone payments, its collaboration with Watson on the development of next-generation progesterone products and its novel bioadhesive drug delivery technologies and other products. Columbia retains all rights necessary to perform its obligations under its agreement with Merck Serono, which relates to sales of Crinone (progesterone gel) outside the US.

8th July 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics